Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P09172

UPID:
DOPO_HUMAN

ALTERNATIVE NAMES:
Dopamine beta-monooxygenase

ALTERNATIVE UPACC:
P09172; Q5T381; Q96AG2

BACKGROUND:
The enzyme Dopamine beta-hydroxylase, alternatively known as Dopamine beta-monooxygenase, is pivotal in the biosynthesis of noradrenaline from dopamine. Its function is integral to the proper operation of the sympathetic nervous system, influencing heart rate, blood pressure, and glucose metabolism.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Orthostatic hypotension 1, a disease characterized by a significant drop in blood pressure upon standing, Dopamine beta-hydroxylase's study offers insights into novel treatment avenues. Exploring this enzyme's mechanisms could lead to breakthroughs in therapeutic interventions for related cardiovascular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.